Skip to main content
OpenTrials
Completed

NCT Number: NCT02234830

Randomized Comparison of ExoSeal® and Angio-Seal Vascular Closure Devices: The CLOSE-UP II Trial

Is the ExoSeal VSD non-inferior to Angio-Seal vascular closure device (VSD) in the incidence of adverse access site related events at 30 days.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Aarhus University Hospital, Aarhus N, Denmark

Loading trial locations.

About this study

Prospective, randomized (1:1) controlled, single blind, single center study in 2000 percutaneous coronary intervention (PCI) patients comparing the ExoSeal VCD (test device) to the AngioSeal VCD (standard comparator). In-hospital and 30 days safety and efficacy endpoints and 6 months safety endpoints will be reported.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Should be able to provide valid informed signed consent
  • PCI procedure including treatment by balloon and/or stent
  • PCI indicated by silent ischemia, stable angina pectoris, non-ST elevation myocardial infarction (NSTEMI) or ST elevation myocardial infarction (STEMI)

Exclusion criteria

  • Only coronary angiography
  • Multiple punctures
  • Active infection
  • Groin haematoma before the closure procedure
  • Sheath size > 7 French
  • Known pseudoaneurysm or arteriovenous (AV)-fistula in the ipsilateral groin
  • Prior arterial surgery in abdomen and/or lower extremities
  • Cardiogenic shock
  • Life expectancy less than one year
  • The patient is a female of childbearing potential with possible pregnancy or a positive pregnancy test within 7 days before the index procedure or is lactating
  • Simultaneous or planned subsequent femoral vein access
  • Allergy to any of the components in the closure material left in the groin
  • Puncture on same site < 30 days
  • Peripheral artery disease patients can be included at operator´s discretion except if heavy calcification is present at the access site which at the operator's discretion precludes insertion of the VCD

Treatment and study plan

Exoseal closure device

Device

Closure device for femoral artery access closure

Angioseal closure device

Device

Closure device for femoral artery access closure

Primary outcomes

  1. Incidence at 30 days of the composite endpoint of access site related major adverse vascular events (MAVE)

    Time frame: 30 days

    This includes: major bleeding and/or bleeding necessitating blood transfusion, pseudoaneurysm with indication for treatment, arteriovenous fistula, groin surgery and/or possible related vascular surgery, infection needing antibiotics.

Secondary outcomes

  1. Time to haemostasis from removing the sheath (AngioSeal) or inserting the device (ExoSeal) until haemostasis

    Time frame: participants will be followed for the duration of hospital stay, an expected average of 2 days

    Insignificant bleeding seen on the bandage or small continuous oozing is considered haemostasis. Continuous oozing will be counted as a Bleeding Academic Research Consortium (BARC) type 1 bleeding event

  2. Device failure

    Time frame: 30 minutes

    Combined endpoint of any mechanic failure, deployment failure and/or immediate profuse bleeding needing prolonged manual compression. Individual endpoints will be reported.

  3. Vasovagal reaction until 5 minutes after end of closure procedure

    Time frame: 30 minuts

  4. Need for new onset of manual compression

    Time frame: 30 days

  5. Pain and discomfort related to the closure procedure

    Time frame: Closure procedure and 30 days

    Assessed on a numerical rating scale (NRS) from 0 (no pain or discomfort) to 10 (worst possible pain or discomfort) Scripted language will be used when discussing pain scores with the patient. Pain and discomfort score will be assessed just before and immediately after the closure procedure and reported. The delta-value will be reported and compared. The patient will be given predefined standardized instructions on how to rate and that only pain and discomfort related to the closure procedure should be assessed

  6. Time to mobilization

    Time frame: participants will be followed for the duration of hospital stay, an expected average of 2 days

    From start of closure procedure to patient is mobilized. Patients treated for ST-elevation myocardial infarction are assessed separately

  7. In-hospital large groin haematoma

    Time frame: participants will be followed for the duration of hospital stay, an expected average of 2 days

    Larger than 5x5 cm measured by ruler in the catheterization laboratory and at discharge

  8. Bleedings according to the BARC definitions

    Time frame: 30 days

    Access site related and non-access site related

  9. Major bleeding and/or bleeding necessitating blood transfusion

    Time frame: 6 months

  10. Pseudoaneurysm with indication for treatment

    Time frame: 30 days and 6 months

  11. Arteriovenous fistula

    Time frame: 30 days and 6 months

  12. Groin surgery and/or possible related vascular surgery

    Time frame: 30 days and 6 months

  13. Infection needing antibiotics

    Time frame: 30 days and 6 months

  14. Need for medical evaluation of possible closure procedure related symptom(s)

    Time frame: 30 days

Sponsors and collaborators

Lead sponsor

Aarhus University Hospital Skejby

Other

Collaborators

  • Abbott Medical Devices
  • Cordis US Corp.

Registry information

Acronym: CLOSE-UP II

Important dates

Study start
2012
Primary completion
2016
Study completion
2017
First posted
Sep 9, 2014
Registry last updated
Jun 1, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.